Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.

Abstract: 1. Presenting ancestral origin information, comprising: receiving a request to display ancestry data of an individual; obtaining ancestry composition information of the individual, the ancestry composition information including information pertaining to a proportion of the individual's genotype data that is deemed to correspond to a specific ancestry; and presenting the ancestry composition information to be displayed.

Abstract: Provided herein is a method, apparatus, and system for teleoperated, functional electric stimulation actuated rehabilitative cycling. Methods may include: receiving, at a master system, rotational input generating master system sensor input having a master system cadence; providing the master system sensor input including the master system cadence to a controller based on the rotational input from a rehabilitation participant or a remote therapist received at the master system; receiving, at a slave system, rotational input from the rehabilitation participant generating slave sensor input having a slave system cadence; providing the slave system sensor input including the slave system cadence to the controller based on the rotational input from the participant received at the slave system; and providing, from the controller, feedback through the master system in response to a difference between the master system cadence and the slave system cadence.

Abstract: Compositions that contain microencapsulated plant beneficial gram negative bacteria are provided, methods of using the compositions to treat plants or plant parts, and treated plants or plant parts are provided.

Abstract: Compositions comprising dried formulations of viable Methylobacterium as well as methods for making and using the formulations are provided. In particular the compositions provide for Methylobacterium formulations with improved viability, shelf-life, and plant or seed treatment characteristics.

Abstract: Compositions comprising dried formulations of viable Methylobacterium as well as methods for making and using the formulations are provided. In particular the compositions provide for Methylobacterium formulations with improved viability, shelf-life, and plant or seed treatment characteristics.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: Embodiments of the present invention relate generally to methods and compositions for producing human prolactin antagonists. Embodiments of the present invention also relate to various methods for improved production of human prolactin antagonists by microorganisms. These microorganisms, including Escherichia coli, can be transformed to enable the expression of human prolactin antagonists at high levels using conventional and inexpensive fermentation conditions and inexpensive induction conditions, as described herein.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: The subject invention relates to methods for detection of mutations in a PKD gene using DHPLC. The invention includes the following aspects: identification of PKD unique sites; design of PKD-specific primers; amplification of PKD-specific products; and analysis of PCR amplified products by DHPLC. The invention further relates to compositions such as identified unique sites and PKD-specific primers, and kits for performing the methods of the invention.

Abstract: A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Abstract: The subject invention relates to methods for detection of mutations in a PKD gene using DHPLC. The invention includes the following aspects: identification of PKD unique sites; design of PKD-specific primers; amplification of PKD-specific products; and analysis of PCR amplified products by DHPLC. The invention further relates to compositions such as identified unique sites and PKD-specific primers, and kits for performing the methods of the invention.

Abstract: The present invention provides a simple, 1-step process for preparing a N-(aryl or heteroaryl)-hydroxyurea comprising reacting the corresponding alcohol, ester or ether with hydroxyurea and acid. This reaction is particularly useful for preparing a benzo[b]thienyl substituted N-hydroxyurea of formula: ##STR1## from compound 1: ##STR2## by reacting compound 1 with hydroxyurea and acid. R.sup.1 is selected from the group consisting of hydrogen, 1-6 carbon alkyl, 1-6 carbon alkoxy, and halogen; R.sup.2 is an 1-4 carbon alkyl; and R.sup.3 is selected from the group consisting of hydrogen, acyl, methyl, ethyl and mixtures thereof. Additional steps to isolate the pure bulk product follow.